What is the role of loratinib in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

Lorlatinib (Lorbrena) was approved in 2018 for patients with ALK-positive metastatic NSCLC who have progressed on crizotinib and at least 1 other ALK inhibitor, or has progressed on alectinib or ceritinib as first ALK inhibitor therapy. Accelerated approval was based on a single, open-label trial (N=215) in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor, in which the overall response rate with loratinib was 48% (4% complete response, 44% partial response), with a median duration of response of 12.5 months. Additionally, in a subgroup of patients with CNS metastases (N=89), the intracranial response rate was 60% (21% complete response, 38% partial response) with a median duration of response of 19.5 months. [188]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!